Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2024

Open Access 01-12-2024 | Obesity | Research

Hyperphagia and impulsivity: use of self-administered Dykens’ and in-house impulsivity questionnaires to characterize eating behaviors in children with severe and early-onset obesity

Authors: Lara Arnouk, Hélène Chantereau, Sophie Courbage, Patrick Tounian, Karine Clément, Christine Poitou, Béatrice Dubern

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Login to get access

Abstract

Background

The determinants of early-onset obesity (< 6 years) are not completely elucidated, however eating behavior has a central role. To date no study has explored eating behavior in children with severe, early-onset obesity. Self-administered questionnaire data from these children were examined to evaluate eating behavior and the etiology of early-onset obesity.

Methods

Children with severe, early-onset obesity (body mass index [BMI] > International Obesity Task Force [IOTF] 30) of different etiologies (hypothalamic obesity [HO], intellectual disability with obesity [IDO], common polygenic obesity [CO]) were prospectively included. BMI history and responses from the Dykens’ Hyperphagia Questionnaire and an in-house Impulsivity Questionnaire at first visit were compared between groups.

Results

This cohort of 75 children (39 girls; mean age ± standard deviation [SD] 10.8 ± 4.4 years) had severe, early-onset obesity at an age of 3.8 ± 2.7 years, with a BMI Z-score of 4.9 ± 1.5. BMI history varied between the 3 groups, with earlier severe obesity in the HO group versus 2 other groups (BMI > IOTF40 at 3.4 ± 1.6 vs. 4.6 ± 1.6 and 8.4 ± 4.1 years for the IDO and CO groups, respectively [P < 0.01]). Absence of adiposity rebound was more prevalent in the HO group (87% vs. 63% and 33% for the IDO and CO groups, respectively [P < 0.01]). The Dykens’ mean total score for the cohort was 22.1 ± 7.2 with no significant between-group differences. Hyperphagia (Dykens’ score > 19) and impulsivity (score > 7) were found in 50 (67%) and 11 children (15%), respectively, with no difference between the HO, IDO and CO groups regarding the number of patients with hyperphagia (10 [67%], 14 [74%], and 26 [63%] children, respectively) or impulsivity (2 [13%], 1 [7%], and 8 [19%] children, respectively). Children with food impulsivity had significantly higher total and severity scores on the Dykens’ Questionnaire versus those without impulsivity.

Conclusion

The Dykens’ and Impulsivity questionnaires can help diagnose severe hyperphagia with/without food impulsivity in children with early-onset obesity, regardless of disease origin. Their systematic use can allow more targeted management of food access control in clinical practice and monitor the evolution of eating behavior in the case of innovative therapeutic targeting hyperphagia.
Literature
1.
go back to reference Dubern B, Mosbah H, Pigeyre M, Clément K, Poitou C. Rare genetic causes of obesity: diagnosis and management in clinical care. Ann Endocrinol. 2022;83(1):63–72.CrossRef Dubern B, Mosbah H, Pigeyre M, Clément K, Poitou C. Rare genetic causes of obesity: diagnosis and management in clinical care. Ann Endocrinol. 2022;83(1):63–72.CrossRef
2.
go back to reference Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120–33.CrossRefPubMed Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120–33.CrossRefPubMed
3.
go back to reference Kim JH, Choi J-H. Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents. Ann Pediatr Endocrinol Metab. 2013;18(4):161–7.CrossRefPubMedPubMedCentral Kim JH, Choi J-H. Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents. Ann Pediatr Endocrinol Metab. 2013;18(4):161–7.CrossRefPubMedPubMedCentral
4.
go back to reference Vlaardingerbroek H, van den Akker ELT, Hokken-Koelega ACS. Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader-Willi syndrome, Bardet-Biedl syndrome and craniopharyngioma versus anorexia nervosa. Endocr Connect. 2021;10(5):R175–88.CrossRefPubMedPubMedCentral Vlaardingerbroek H, van den Akker ELT, Hokken-Koelega ACS. Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader-Willi syndrome, Bardet-Biedl syndrome and craniopharyngioma versus anorexia nervosa. Endocr Connect. 2021;10(5):R175–88.CrossRefPubMedPubMedCentral
5.
go back to reference Huvenne H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158–73.CrossRefPubMedPubMedCentral Huvenne H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158–73.CrossRefPubMedPubMedCentral
6.
go back to reference Müller HL, Tauber M, Lawson EA, Özyurt J, Bison B, Martinez-Barbera J-P, et al. Hypothalamic syndrome. Nat Rev Dis Prim. 2022;8(1):24.CrossRefPubMed Müller HL, Tauber M, Lawson EA, Özyurt J, Bison B, Martinez-Barbera J-P, et al. Hypothalamic syndrome. Nat Rev Dis Prim. 2022;8(1):24.CrossRefPubMed
8.
go back to reference Khera AV, Chaffin M, Wade KH, Zahid S, Brancale J, Xia R, et al. Polygenic prediction of weight and obesity trajectories from birth to adulthood. Cell. 2019;177(3):587-96.e9.CrossRefPubMedPubMedCentral Khera AV, Chaffin M, Wade KH, Zahid S, Brancale J, Xia R, et al. Polygenic prediction of weight and obesity trajectories from birth to adulthood. Cell. 2019;177(3):587-96.e9.CrossRefPubMedPubMedCentral
9.
go back to reference Kleinendorst L, Abawi O, van der Kamp HJ, Alders M, Meijers-Heijboer HEJ, van Rossum EFC, et al. Leptin receptor deficiency: a systematic literature review and prevalence estimation based on population genetics. Eur J Endocrinol. 2020;182(1):47–56.CrossRefPubMed Kleinendorst L, Abawi O, van der Kamp HJ, Alders M, Meijers-Heijboer HEJ, van Rossum EFC, et al. Leptin receptor deficiency: a systematic literature review and prevalence estimation based on population genetics. Eur J Endocrinol. 2020;182(1):47–56.CrossRefPubMed
10.
go back to reference Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obes. 2007;15(7):1816–26.CrossRef Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obes. 2007;15(7):1816–26.CrossRef
11.
go back to reference Welham A, Lau J, Moss J, Cullen J, Higgs S, Warren G, et al. Are Angelman and Prader-Willi syndromes more similar than we thought? Food-related behavior problems in Angelman, Cornelia de Lange, fragile X, Prader-Willi and 1p36 deletion syndromes. Am J Med Genet A. 2015;167A(3):572–8.CrossRefPubMed Welham A, Lau J, Moss J, Cullen J, Higgs S, Warren G, et al. Are Angelman and Prader-Willi syndromes more similar than we thought? Food-related behavior problems in Angelman, Cornelia de Lange, fragile X, Prader-Willi and 1p36 deletion syndromes. Am J Med Genet A. 2015;167A(3):572–8.CrossRefPubMed
12.
go back to reference Sherafat-Kazemzadeh R, Ivey L, Kahn SR, Sapp JC, Hicks MD, Kim RC, et al. Hyperphagia among patients with Bardet-Biedl syndrome. Pediatr Obes. 2013;8(5):e64–7.CrossRefPubMedPubMedCentral Sherafat-Kazemzadeh R, Ivey L, Kahn SR, Sapp JC, Hicks MD, Kim RC, et al. Hyperphagia among patients with Bardet-Biedl syndrome. Pediatr Obes. 2013;8(5):e64–7.CrossRefPubMedPubMedCentral
13.
go back to reference Wang L, Shoemaker AH. Eating behaviors in obese children with pseudohypoparathyroidism type 1a: a cross-sectional study. Int J Pediatr Endocrinol. 2014;2014(1):21.CrossRefPubMedPubMedCentral Wang L, Shoemaker AH. Eating behaviors in obese children with pseudohypoparathyroidism type 1a: a cross-sectional study. Int J Pediatr Endocrinol. 2014;2014(1):21.CrossRefPubMedPubMedCentral
14.
go back to reference Maillard AM, Hippolyte L, Rodriguez-Herreros B, Chawner SJRA, Dremmel D, Agüera Z, et al. 16p11.2 Locus modulates response to satiety before the onset of obesity. Int J Obes. 2016;40(5):870–6.CrossRef Maillard AM, Hippolyte L, Rodriguez-Herreros B, Chawner SJRA, Dremmel D, Agüera Z, et al. 16p11.2 Locus modulates response to satiety before the onset of obesity. Int J Obes. 2016;40(5):870–6.CrossRef
15.
go back to reference Courbage S, Poitou C, Le Beyec-Le BJ, Karsenty A, Lemale J, Pelloux V, et al. Implication of heterozygous variants in genes of the leptin-melanocortin pathway in severe obesity. J Clin Endocrinol Metab. 2021;106(10):2991–3006.CrossRefPubMed Courbage S, Poitou C, Le Beyec-Le BJ, Karsenty A, Lemale J, Pelloux V, et al. Implication of heterozygous variants in genes of the leptin-melanocortin pathway in severe obesity. J Clin Endocrinol Metab. 2021;106(10):2991–3006.CrossRefPubMed
16.
go back to reference Zorn S, von Schnurbein J, Schirmer M, Brandt S, Wabitsch M. Measuring hyperphagia in patients with monogenic and syndromic obesity. Appetite. 2022;178:106161.CrossRefPubMed Zorn S, von Schnurbein J, Schirmer M, Brandt S, Wabitsch M. Measuring hyperphagia in patients with monogenic and syndromic obesity. Appetite. 2022;178:106161.CrossRefPubMed
17.
go back to reference Wardle J, Guthrie CA, Sanderson S, Rapoport L. Development of the children’s eating behaviour questionnaire. J Child Psychol Psychiatry. 2001;42(7):963–70.CrossRefPubMed Wardle J, Guthrie CA, Sanderson S, Rapoport L. Development of the children’s eating behaviour questionnaire. J Child Psychol Psychiatry. 2001;42(7):963–70.CrossRefPubMed
18.
go back to reference Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133–40.CrossRefPubMedPubMedCentral Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133–40.CrossRefPubMedPubMedCentral
19.
go back to reference Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–70.CrossRefPubMed Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–70.CrossRefPubMed
20.
go back to reference Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A. Body Mass Index variations: centiles from birth to 87 years. Eur J Clin Nutr. 1991;45(1):13–21.PubMed Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A. Body Mass Index variations: centiles from birth to 87 years. Eur J Clin Nutr. 1991;45(1):13–21.PubMed
21.
go back to reference Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;7(4):284–94.CrossRefPubMed Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;7(4):284–94.CrossRefPubMed
22.
go back to reference Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859–68.CrossRefPubMedPubMedCentral Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859–68.CrossRefPubMedPubMedCentral
23.
go back to reference Hill B, Bergmeier H, Incollingo Rodriguez AC, Barlow FK, Chung A, Ramachandran D, et al. Weight stigma and obesity-related policies: a systematic review of the state of the literature. Obes Rev. 2021;22(11):e133333.CrossRef Hill B, Bergmeier H, Incollingo Rodriguez AC, Barlow FK, Chung A, Ramachandran D, et al. Weight stigma and obesity-related policies: a systematic review of the state of the literature. Obes Rev. 2021;22(11):e133333.CrossRef
24.
go back to reference Wabitsch M, Fehnel S, Mallya UG, Sluga-O’Callaghan M, Richardson D, Price M, et al. Understanding the patient experience of hunger and improved quality of life with setmelanotide treatment in POMC and LEPR deficiencies. Adv Ther. 2022;39(4):1772–83.CrossRefPubMedPubMedCentral Wabitsch M, Fehnel S, Mallya UG, Sluga-O’Callaghan M, Richardson D, Price M, et al. Understanding the patient experience of hunger and improved quality of life with setmelanotide treatment in POMC and LEPR deficiencies. Adv Ther. 2022;39(4):1772–83.CrossRefPubMedPubMedCentral
25.
go back to reference Wabitsch M, Farooqi S, Flück CE, Bratina N, Mallya UG, Stewart M, et al. Natural history of obesity due to POMC, PCSK1, and LEPR deficiency and the impact of setmelanotide. J Endocr Soc. 2022;6(6):bvac057.CrossRefPubMedPubMedCentral Wabitsch M, Farooqi S, Flück CE, Bratina N, Mallya UG, Stewart M, et al. Natural history of obesity due to POMC, PCSK1, and LEPR deficiency and the impact of setmelanotide. J Endocr Soc. 2022;6(6):bvac057.CrossRefPubMedPubMedCentral
26.
go back to reference Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold J-A, Kimonis V, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011;155A(5):1040–9.CrossRefPubMedPubMedCentral Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold J-A, Kimonis V, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011;155A(5):1040–9.CrossRefPubMedPubMedCentral
27.
go back to reference Chamay-Weber C, Combescure C, Lanza L, Carrard I, Haller DM. Screening obese adolescents for binge eating disorder in primary care: the adolescent binge eating scale. J Pediatr. 2017;185:68–72.CrossRefPubMed Chamay-Weber C, Combescure C, Lanza L, Carrard I, Haller DM. Screening obese adolescents for binge eating disorder in primary care: the adolescent binge eating scale. J Pediatr. 2017;185:68–72.CrossRefPubMed
28.
go back to reference Quilliot D, Brunaud L, Mathieu J, Quenot C, Sirveaux M-A, Kahn JP, et al. Links between traumatic experiences in childhood or early adulthood and lifetime binge eating disorder. Psychiatry Res. 2019;276:134–41.CrossRefPubMed Quilliot D, Brunaud L, Mathieu J, Quenot C, Sirveaux M-A, Kahn JP, et al. Links between traumatic experiences in childhood or early adulthood and lifetime binge eating disorder. Psychiatry Res. 2019;276:134–41.CrossRefPubMed
Metadata
Title
Hyperphagia and impulsivity: use of self-administered Dykens’ and in-house impulsivity questionnaires to characterize eating behaviors in children with severe and early-onset obesity
Authors
Lara Arnouk
Hélène Chantereau
Sophie Courbage
Patrick Tounian
Karine Clément
Christine Poitou
Béatrice Dubern
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
Obesity
Obesity
Published in
Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-024-03085-1

Other articles of this Issue 1/2024

Orphanet Journal of Rare Diseases 1/2024 Go to the issue